YAP, a major downstream effector of the Hippo signaling pathway, is an important regulator of cell proliferation. The ability of YAP to regulate G2/M gene expression is dependent on the Myb-MuvB (MMB) complex, consisting of the evolutionary MuvB core complex and the facultative B-MYB subunit, a transcription factor. Here we show that YAP directly binds to B-MYB. Disruption of the YAP/B-MYB interaction by overexpression of the YAP binding domain of B-MYB results in errors in cell division. We also show that YAP and MMB interact in vivo in the developing heart. Genome studies revealed that YAP and MMB regulate an overlapping set of cell cycle genes in cardiomyocytes. Cardiac specific deletion of the LIN9 subunit of MMB prevents the upregulation of cell cycle genes and the increased proliferation of cardiomyocytes lacking the Hippo-signaling component SAV1. Similarly, we find that proliferation of postnatal cardiomyocytes induced by constitutive active YAP depends on MMB. Our findings provide new insights in the YAP induced proliferation of cardiomyocytes through the functional interaction with MMB.
INTRODUCTION
The correct regulation of the cell cycle is essential for normal development and, when disturbed, can lead to a number of diseases. Changes in transcriptional activity ensure that proteins required for different cell-cycle phases or developmental states are produced at the correct time. The evolutionary conserved MuvB multiprotein complex functions as one of the transcriptional regulators of cell cycle genes (Sadasivam & DeCaprio, 2013; Fischer & Müller, 2017) . Dependent on its interactions with different binding partners, MuvB can either repress or activate transcription. Specifically, when MuvB, consisting of the five proteins LIN9, LIN52, LIN54, LIN37 and RBBP4, interacts with the p130 retinoblastoma protein paralog, and with E2F4 and DP1, it forms the DREAM complex, which represses E2F-dependent gene expression in quiescent cells and in early G1 (Litovchick et al, 2007; Schmit et al, 2007) . Upon cell cycle entry, p130, E2F4 and DP1 dissociate from the complex and the MuvB core associates with the transcription factor B-MYB (Sadasivam et al, 2012; Pilkinton et al, 2007; Schmit et al, 2007; Osterloh et al, 2007) . This Myb-MuvB (MMB) complex activates a set of genes required for mitosis and cytokinesis.
We recently observed that MMB and the transcriptional coactivator YAP co-regulate an overlapping set of late cell cycle genes (Pattschull et al, 2019) . The activity of YAP and related TAZ is controlled by the highly conserved Hippo pathway, a kinase cascade, that regulates proliferation and organ size during development (Hong & Guan, 2012) . When the Hippo pathway is active, the upstream MST1/2 kinases together with Salvador (SAV1) phosphorylate and activate the terminal LATS1/2 kinase (Meng et al, 2016) . LATS1/2 in turn phosphorylate YAP and TAZ, which results either in cytoplasmic retention by 14-3-3 proteins or SCFmediated proteasomal degradation of YAP/TAZ (Meng et al, 2016) . In contrast, when Hippo is inactive, YAP/TAZ enter the nucleus and act as transcriptional coactivators predominantly by binding to DNA through TEAD transcription factors. Recent genome wide studies revealed that YAP/TEAD preferentially binds to distant enhancers (Zanconato et al, 2015; Galli et al, 2015; Stein et al, 2015) . The binding of YAP to enhancers of G2/M genes promotes the chromatinassociation of B-MYB to MMB-bound promoters through chromatin-looping, providing an explanation for the co-activation of late cell cycle genes by YAP and MMB (Pattschull et al, 2019) .
The Hippo pathway and its downstream effectors YAP and TAZ are involved in cardiac development and has been implicated in heart regeneration after tissue damage (Liu & Martin, 2019; Wang et al, 2018) . For example, cardiac-specific deletion of the Hippo kinases LATS1/2 or the scaffold protein SAV1 results in heart enlargement and increased proliferation of embryonal and postnatal cardiomyocytes due to increased YAP activity (Heallen et al, 2011; Heallen et al, 2013) . Furthermore, expression of active YAP promotes proliferation of postnatal cardiomyocytes and induces a fetal-like cell state in adult cardiomyocytes (Gise et al, 2012; Monroe et al, 2019) . Conversely, deletion of YAP in the embryonic heart reduces cardiomyocyte proliferation and results in myocardial hypoplasia and embryonic lethality (Xin et al, 2011) . Recent studies also demonstrate that Hippo-deficient mice or mice expressing active YAP show a better outcome after myocardial infarction (Heallen et al, 2013; Morikawa et al, 2015; Leach et al, 2017; Xin et al, 2013; Lin et al, 2014) . Together, these studies identify YAP as an important regulator of cardiomyocyte proliferation and cardiac regeneration.
Whether the crosstalk between YAP and MMB contributes to cardiomyocyte proliferation during cardiac development has not yet been investigated.
In the current study, we demonstrate the WW-domains of YAP directly interact with a newly identified YAP-binding domain in the N-terminal part of B-MYB. Based on the binding studies we designed a fragment of B-MYB, MY-COMP, that can interfere with the YAP-B-MYB association. Expression of MY-COMP results in errors in cell division highlighting the importance of the YAP-MMB interaction for normal cell cycle progression. We further show that YAP and MMB interact in developing cardiomyocytes. Genetic studies indicate that this interaction is essential for increased mitosis of Hippo-deficient cardiomyocytes. Additionally, we demonstrate that YAP driven proliferation of postmitotic cardiomyocytes is dependent of MMB. Together, our data suggests that the YAP-MMB interaction is essential for cell cycle progression of cardiomyocytes, underscoring the functional relevance of the crosstalk between these two pathways for proper heart development.
RESULTS

B-MYB interacts with the tandem WW domains of YAP
The Hippo coactivator YAP interacts with the B-MYB subunit of the MMB complex in mammalian cells to regulate the expression of cell cycle genes (Pattschull et al, 2019) . To gain further insights into the interplay between YAP and MMB and to develop tools to interfere with the interaction, we mapped the domain of YAP that is required for its ability to bind to B-MYB.
To do so, we performed co-immunoprecipitation experiments with HA-B-MYB and a set of truncated flag-tagged YAP constructs.
In these assays, B-MYB interacted with YAP only when the tandem WW domains were present. B-MYB did not interact with the C-terminal transactivation domain or the PDZ-binding motif ( Figure 1A ,B,C). Internal deletion of the tandem WW domains abolished the binding, confirming that these domains are required for the YAP-B-MYB interaction ( Figure 1D ). To verify that the YAP WW domains mediate the interaction with B-MYB, we performed pulldown experiments with recombinant GST fused to the N-terminal part of YAP containing the TEADbinding and WW domains (GST-TEAD-WW1/2) or just the two WW domains (GST-WW1/2) ( Figure 1E ). Recombinant GST-proteins were incubated with extracts of HeLa cells expressing HA-tagged B-MYB and bound B-MYB was detected by immunoblotting with an anti-HA antibody. In these experiments, HA-B-MYB specifically bound to GST-TEAD-WW1/2 and GST-WW1/2 and but not to GST alone ( Figure 1F ). YAP binds to DNA mainly by binding to TEAD transcription factors. We therefore used HA-tagged TEAD4 as a positive control. HA-TEAD4 only bound to GST-TEAD-WW1/2 containing the TEAD-binding domain, but not to GST alone or to GST-WW1/2. HA-tagged EB1, which was used as a negative control, did not bind to any of the GST constructs. Using GST-fusion proteins containing either one of the two WW domains (GST-WW1 and GST-WW2), we found that B-MYB can independently bind to both WW domains ( Figure 1G ). However, B-MYB more strongly interacted with the first WW domain and strongest binding of B-MYB was observed when both WW domains were present ( Figure 1G) .
B-MYB binds to the WW domains of YAP through a PPXY motif
We have previously shown that the N-terminal part of B-MYB comprised of the amino acids 1-410, but not the C-terminus from 411-700, interacts with YAP (Pattschull et al, 2019) . Since the MMB-interaction domain (MBD) is located in the C-terminal region of B-MYB, this result suggested that the binding of YAP to B-MYB is not mediated by binding of YAP to the MuvB core (Guiley et al, 2015) . We now wanted to map the region of B-MYB that binds to YAP more precisely and we asked whether B-MYB directly binds to YAP.
Pulldown experiments with GST-WW1 and with a set of HA-tagged B-MYB deletion mutants revealed that the minimal binding site for YAP is located between amino acids 80 and 241 of B-MYB (Figure 2A,B ). For example, B-MYB(2-241) robustly bound to YAP whereas B-MYB(2-79) and B-MYB(242-410) failed to bind to YAP ( Figure 2B ). The interaction between B-MYB and YAP could be indirect since exogenously expressed HA-B-MYB likely associates with additional cellular proteins. To test whether the interaction between B-MYB and YAP is direct, we incubated purified, recombinant his-tagged B-MYB(2-241) with GST-WW1, GST-WW2 or with GST-WW1/2. Purified his-B-MYB(2-241) specifically interacted with GST-WW1/2, but not with GST, indicating that the binding between B-MYB and YAP is direct ( Figure 2C ).
Recombinant his-B-MYB bound only weakly to the individual WW domains, consistent with the weaker binding of HA-tagged B-MYB to the single WW domains compared to the tandem WW domains ( Figure 2C , see Figure 1G ). This indicates that both WW domains are necessary for an efficient interaction with B-MYB.
The WW domain is a protein-interaction domain characterized by two tryptophan-residues separated by 20 to 22 amino acids. Ligands for the WW domain are proline-rich regions such as the PPXY motif (Macias et al, 2015; Chen & Sudol, 1995) . B-MYB harbors a PPXY sequence (PPVY) between the N-terminal DNA-binding domain and the central transactivation domain (Figure 2A ). Importantly, this PPXY motif is located in the region of B-MYB that was found to interact with YAP, leading to the hypothesis that it is involved in binding to YAP. We directly tested this idea by performing pulldown experiments with a deletion mutant of recombinant B-MYB lacking the PPXY sequence (∆PPXY). Compared to his-tagged B-MYB(2-241), binding of his-B-MYB(2-241,∆PPXY) to the WW domains of YAP was strongly reduced ( Figure 2D ). To investigate whether the PPXY motif is also required for the interaction with YAP in the context of the full-length B-MYB protein in cells, we next performed coimmunoprecipitation experiments of flag-tagged YAP with HA-B-MYB and with HA-B-MYB(∆PPXY). Binding of B-MYB to YAP was again strongly reduced when the PPXY sequence was deleted ( Figure 2E ,F). Taken together, these results indicate that the YAP interacting region of B-MYB is located between amino acid 80 and 241 of B-MYB and involves a PPXY motif.
Overexpression of the YAP binding domain disrupts the B-MYB-YAP interaction and results in errors in cell division
Since B-MYB and YAP directly interact, we next asked whether overexpression of the YAP binding domain of B-MYB can interfere with the interaction of B-MYB with YAP due to steric hindrance ( Figure 3A Strikingly, expression of MY-COMP resulted in a pronounced increase in bi-and multinucleated cells and in cells with micronuclei ( Figure 3G ,H). Importantly, a shortened version of MY-COMP (HA-NLS-B-MYB(2-79)), which does not bind to YAP showed no such effect. The effect of MY-COMP is not due to interference with the DNA-binding of B-MYB, because expression of MY-COMP with a mutation in the DNA-binding domain that has been shown to prevent the interaction with DNA (Werwein et al, 2012) , showed the same phenotype ( Figure 3H ). Importantly, deletion of the PPXY motif in MY-COMP abolished the effect on biand multinucleation and decreased micronuclei formation, indicating that the ability to induce cell division errors correlates with the ability to disrupt the YAP-B-MYB interaction. B-MYB constructs were expressed at comparable levels and we did not find any changes in B-MYB and YAP expression levels and in YAP-phosphorylation at S127 in these cells ( Figure 3F ).
Phosphorylation of S127 was used as a proxy for YAP activity as it is a key residue for phosphorylation by the Hippo kinases LATS1/2. Taken together, these experiments provide evidence for the importance of the B-MYB-YAP interaction for normal cell cycle progression.
YAP interacts with MMB in cardiomyocytes
We next asked whether the interaction between B-MYB and YAP is of relevance in vivo. YAP is known to promote proliferation of embryonic cardiomyocytes during development whereas inhibition of YAP by the Hippo cascade suppresses cardiomyocyte proliferation (Heallen et al, 2011; Xin et al, 2011; Gise et al, 2012) . Activated YAP or loss of Hippo signaling can also extend the neonatal proliferation of cardiomyocytes to postnatal stages, where proliferation is normally very low (Gise et al, 2012; Heallen et al, 2011; Monroe et al, 2019) . Whether MuvB impacts on the ability of YAP to regulate cardiomyocyte gene expression and to promote cardiomyocyte proliferation is unclear. We first investigated whether YAP and B-MYB interact in the heart. PLA showed that YAP indeed interacted with B-MYB in developing cardiomyocytes ( Figure 4A ,B). The interaction was specific, as demonstrated by the loss of the PLA signal upon siRNA-mediated depletion of B-MYB ( Figure 4A ,B). YAP also interacted with LIN9, a core subunit of the MuvB complex that is required for binding of B-MYB to MuvB (Guiley et al, 2018) , providing further evidence for an interaction between YAP and MMB in cardiomyocytes.
Hippo and MMB regulate an overlapping set of genes in embryonic cardiomyocytes
To explore the connection between the Hippo-YAP pathway and MMB in vivo in the heart, we deleted the Hippo pathway member Salvador (Sav1), a scaffold protein that is required for Hippo kinase activity, and the MMB subunit Lin9 in cardiac precursor cells. Cardiac specific deletion of Lin9 and Sav1 was achieved by using mouse strains with conditional (floxed) alleles of Sav1 and Lin9 in combination with Nkx2.5-Cre (Cai et al, 2010) . Phosphorylation of YAP on S127 was reduced, indicating that YAP is hyperactivated in Sav1 deficient hearts (Supplementary Figure S1A ). First, we explored the impact of Lin9 mutation on the transcriptional program of Hippo-deficient cardiomyocytes by performing RNA-seq using RNA isolated from embryonic heart ventricles of mice carrying cardiac specific deletions of Sav1 alone, Lin9 alone or Sav1 and Lin9 together.
In Sav1 knockout hearts, E2F target genes and other gene sets related to cell cycle regulation were enriched after inactivation of Hippo-signaling ( Figure 5A , Supplementary Figure S1B ). Strikingly, the activation of these gene sets was suppressed by the simultaneous deletion of Lin9 together with Sav1, indicating that the elevated expression of these genes in Sav1 mutant hearts requires the function of MMB ( Figure 5A ,B, Supplementary Figure S1B ). By qPCR we independently validated that a set of cell cycle target genes were activated in Sav1 mutated hearts, downregulated in Lin9 mutated hearts and remained downregulated in hearts isolated from double mutant embryos ( Figure 5C ).
To find out whether cell cycle genes upregulated in Sav1 hearts are direct targets of MMB, we performed chromatin immunoprecipitation experiments followed by high-throughput sequencing (ChIP-seq). We identified 3357 bindings sites for LIN9 in the fetal heart and 2672 binding sites in the postnatal heart. While the reduced expression of LIN9 in postnatal hearts likely contributes to the lower number of LIN9 sites in postnatal hearts (see below), the overall binding pattern of LIN9 was similar at the two developmental time points and the shared binding sites reflect high confident LIN9-binding sites ( Figure 5D , Supplementary Figure S1C ).
By comparison with previously reported ChIP-seq data of histone modifications characteristic for active promoters and enhancers, most LIN9 binding sites are located in active promoters while less than 5% of LIN9 sites are found in enhancers or super-enhancers ( Figure 5E , Supplementary Figure S1C ).
To identify the direct targets of LIN9 in the heart, we plotted changes in gene expression upon deletion of Lin9 against the density of promoter-bound LIN9. This revealed a correlation between genes that are activated by LIN9 (i.e. that are downregulated after deletion of Lin9) and promoter binding of LIN9 ( Figure 5F ). In particular, LIN9 strongly bound to the promoters of cell cycle genes and E2F target genes ( Figure 5G ). While overall LIN9-binding correlated with expression changes, LIN9 only weakly bound to the promoters of some gene sets that are also downregulated in Lin9 knockout hearts, including genes related to mitochondrial function, oxidative phosphorylation, metabolism, heart muscle contraction and ion channel activity ( Figure 5G , Supplementary Figure S1D ,E). Weak binding to the promoters of these genes suggests that downregulation of these genes is an indirect consequence of loss of Lin9.
Strikingly, when we evaluated the relationship between changes in gene expression upon cardiac-specific deletion of Sav1 and LIN9-promoter occupancy, we found that promoters of genes activated in Sav1 knockout hearts were also bound by LIN9 ( Figure 5H ). In contrast to LIN9 which bound to active promoters, ChIP-seq of YAP in E16.5 hearts showed that YAP predominantly binds to enhancers and super-enhancers rather than to promoters (Supplementary Figure S2A ,B,C), which is consistent with recent genome wide studies in human cell lines (Galli et al, 2015; Stein et al, 2015; Pattschull et al 2019; Zanconato et al, 2015) . Consequently, there was little overlap in the binding of YAP and LIN9 (Supplementary Figure S2B ,C). This supports the idea that YAP does not regulate cell cycle promoters by directly binding to their promoters, but that YAP instead activates MMB-regulated cell cycle promoters from distant enhancers as previously shown in human MCF10A cells (Pattschull et al, 2019) . In summary, the deletion of Sav1 hyperactivates YAP, which in turn results in induction of cell cycle genes in a LIN9 dependent manner.
Lin9 is required for proliferation and mitosis of Hippo-deficient embryonic cardiomyocytes
We next examined the effect of MMB inactivation on proliferation of Sav1 mutated cardiomyocytes. To assess proliferation, we stained E13.5 heart sections for the cell cycle marker Ki67. Cardiomyocytes were identified by co-staining for cardiac troponin T (cTnT). The proportion of Ki67-positive cardiomyocytes was significantly increased in Nkx2.5-Cre;Sav fl/fl hearts compared to control hearts with wildtype Sav1, indicating that loss of SAV1 promoted cardiomyocyte proliferation as has been reported previously ( Figure 6A ,B). The fraction of cardiomyocytes staining positive for phosphorylated histone H3 (pH3), a marker of mitotic cells, was also increased in Nkx2.5-Cre;Sav1 fl/fl hearts ( Figure 6C ,D). In contrast, proliferation and mitosis were strongly reduced by inactivation of Lin9 and the increase in proliferation by Sav1 deletion was blocked in Sav1,Lin9 double mutant cardiomyocytes ( Figure 6A -D). These genetic experiments suggest that the proliferative phenotype due to the loss of the Hippo pathway member SAV1 is dependent on the MMB subunit LIN9.
We could not analyze the contribution of MMB to the Hippo-deficient phenotype at later embryonic or postnatal stages with this experimental system, because deletion of Lin9 in heart progenitor cells by Nkx2.5-Cre resulted in embryonic lethality before embryonic day 18.5 (Supplementary Figure S3A ). H&E stained embryonic heart sections showed that the thickness of the compact myocardium of both ventricles was reduced in Lin9 knockout mice at E13.5 (Supplementary Figure S3B ,C). Examination of H&E stained sections at higher magnification showed that nuclei in mutant cardiomyocytes were enlarged and pleomorphic (Supplementary 
Lin9 is required for proliferation of Hippo-deficient postnatal cardiomyocytes
To circumvent the embryonic lethality associated with deleting Lin9 in early cardiac precursors, we used a transgenic mouse line with Cre recombinase driven by the alpha-MHC-promoter, which is active at a later stage during heart development compared to Nkx2.5-Cre (Agah et al, 1997 ). a-MHC-Cre; Lin9 fl/fl mice survived into adulthood without any obvious heart phenotype and without differences in the heart to body weight when compared to heterozygous control animals ( Figure 7A ,B,C). The lack of a heart phenotype in a-MHC-Cre; Lin9 fl/fl mice is not due to inefficient deletion of Lin9 in the heart as revealed by combining with a mT/mG reporter strain (Muzumdar et al, 2007) . Upon Cre-induced recombination of the mT/mG reporter gene, membrane bound Tomato (mT) is removed and the expression of membrane bound EGFP (mG) is activated ( Figure 7D ). FACS analysis revealed that recombination in the heart of a-MHC-Cre; Lin9 fl/fl mice was almost 100% (Figure 7E ,F).
Thus, while early cardiac deletion of Lin9 in Nkx-Cre mice caused a dramatic and lethal phenotype, the complete deletion of Lin9 at a later stage of development did not result in an obvious phenotype, despite the fact that Lin9 is expressed in the postnatal heart in wildtype mice (Supplementary Figure S4A ,B). LIN9 also remained associated with the chromatin in postnatal hearts as determined by ChIP-seq ( Figure 5E, Supplementary Figure S1C ). The expression of the remaining MuvB core subunits also only modestly varied between the different developmental time points (Supplemental Figure S4A ,B). Stronger changes in expression were observed with Mybl2, which declined at P1 compared to E16.5 and further decreased at P10, a pattern that was also confirmed on protein level (Supplemental Figure   S4A 
Cardiomyocyte proliferation by activated YAP requires LIN9
To directly test whether increased cardiomyocyte proliferation due to activated YAP depends on MMB, we transduced cardiomyocytes with an adenovirus expressing a constitutive active version of YAP in which S127, the site of the inactivating phosphorylation by LATS kinases, is mutated to alanine ( Figure 8A ). To determine the requirement of MMB for YAP(S127A) induced proliferation, we used cardiomyocytes isolated from mice with a conditional allele of Lin9 (Lin9 fl/fl ) and expressing a hormone inducible CreER recombinase that can be activated by the addition of 4-hydroxytamoxifen (4-OHT). Treatment with 4-OHT resulted in efficient deletion of Lin9 in neonatal Lin9 fl/fl ; CreER cardiomyocytes ( Figure 8B ). Expression of YAP(S127A) robustly induced mitotic entry of embryonic E14.5 and postnatal P1 cardiomyocytes, as reported before (Xin et al, 2011; Gise et al, 2012) (Figure 8C ,D, Supplementary Figure S4A,B) . Importantly, when Lin9 was deleted by treatment with 4-OHT, the increase in pH3 positive cells by YAP(S127A) was strongly suppressed, indicating that YAP requires MMB to promote cardiomyocyte proliferation ( Figure 8C ,D, Supplementary   Figure S5A ,B). Importantly, the ability of YAP(S127A) to stimulate cardiomyocyte proliferation and to promote entry into mitosis was abolished by deletion of the YAP WW domains, which mediate the binding to MMB ( Figure 8E ,F, Supplementary Figure S5C ,D). Similarly, a point mutant of YAPS127A deficient in binding to TEAD [YAP(S127A/S94A)], was also not able to increase proliferation and mitosis, indicating that these functions of YAP are TEAD dependent ( Figure 8E ,F, Supplementary Figure S5C ,D).
We next asked whether proliferation of cardiomyocytes depends on the YAP-B-MYB interaction. We infected embryonal cardiomyocytes with an adenovirus expressing MY-COMP coupled to GFP through a T2A self-cleaving peptide. Infected cardiomyocytes were detected by their green fluorescence and by staining for cTnT (Supplementary Figure S5E ). Staining for phospho-H3 showed that expression of MY-COMP strongly suppressed mitosis of embryonal cardiomyocytes ( Figure 8G, Supplementary Figure S5E ). Importantly, this effect was diminished by deletion of the PPXY motif in MY-COMP. Taken together these observations are consistent with the notion that YAP requires MMB to co-activate mitotic genes and promote mitotic entry of cardiomyocytes.
In another line of evidence, we investigated whether YAP is able to regulate MMB target genes in differentiated C2C12 myotubes. Co-immunoprecipitations confirmed that B-MYB and YAP interact in C2C12 myoblasts ( Figure 8H ). MMB target genes were expressed at high levels in asynchronous growing C2C12 cells and were downregulated during myogenic differentiation ( Figure 8I ). Expression of a constitutive active YAP(S127A) partially reverted the downregulation of MMB target genes in differentiated cells ( Figure 8I ,J). Importantly, like the induction of proliferation of cardiomyocytes, the upregulation of MMB target genes by YAP was dependent on the WW and the TEAD-binding domains ( Figure 8K ). Strikingly activation of YAP target genes that are not regulated from distant enhancers but by binding of YAP to the proximal promoter, such as Ctgf and Cyr61, was independent of the WW domain. Taken together these data support the notion that YAP activates cell cycle genes from distant enhancers in a MMB dependent-manner.
DISCUSSION
One of the best characterized biological responses of YAP, the central downstream effector of the Hippo signaling pathway, is the induction of cell proliferation (Totaro et al, 2018) . We have recently shown that the MMB complex is required for activation of G2/M genes by YAP (Pattschull et al, 2019) . In this study we demonstrate a direct association between the MMB subunit B-MYB and YAP and we show that this interaction is of importance in vivo in for the development of the normal heart ( Figure 8L ). (Zhao et al, 2009 ). Our results suggest that at least parts of these effects are mediated by the association of B-MYB with the WW domains. Targeting WW domain mediated interactions by MY-COMP, or by more potent inhibitors based on MY-COMP, may prove a valid strategy to inhibit the oncogenic pro-proliferative functions of YAP. Such inhibitors could serve as selective therapeutic target in cancers with high levels of YAP.
Recent studies have shown that the Hippo-YAP pathway plays essential roles during heart development and heart regeneration (Wang et al, 2018) . While the deletion of YAP in embryonic heart impairs cardiomyocyte division, the expression of constitutively active YAP promotes cardiomyocyte proliferation (Gise et al, 2012; Xin et al, 2011; Del Re et al, 2013) . We now show that MMB is required for the ability of YAP to induce cell division in this tissue. First, we used a mouse model in which cell cycle genes were induced in embryonic hearts by activation of YAP through the knockout of the Hippo pathway protein Sav1. These genes were not induced when the MuvB subunit Lin9 was deleted together with Sav1.
Proliferation of cardiomyocytes is also dependent on both MMB and YAP since deletion of Lin9 abolishes the enhanced proliferation induced by deletion of Sav1. This requirement is not limited to the embryonic heart but the same dependency on Lin9 for cardiomyocyte proliferation was also observed in postnatal hearts using Lin9 / Sav1 double knockout mice expressing the Cre transgene from the alpha-MHC promoter. Further evidence for this dependency on LIN9 comes from experiments using cultured embryonal or postnatal cardiomyocytes with a conditional Lin9 allele and a hormone inducible Cre recombinase. Adenoviral expression of activated YAP was only able to induce mitosis when Lin9 was present but not after Cre-mediated deletion of Lin9. Although it is possible that YAP and MMB could independently induce a similar set of genes required for cell cycle regulation, our findings that B-MYB and YAP directly interact, that the YAP induced cardiomyocyte proliferation depends on its WW domains and that cardiomyocyte mitosis is inhibited by MY-COMP, support the notion that the synergy is a result of the interaction between YAP and MMB.
Genome binding studies in embryonic hearts demonstrated that LIN9 binds to the promoters of cell cycle genes activated by YAP, indicating that these genes are direct targets of MMB.
By ChIP-seq, YAP does not colocalize with LIN9 to the promoters of cell cycle genes but instead binds to enhancers, consistent with recent data from human cancer cell lines where YAP also predominantly binds to distant sites (Zanconato et al, 2015; Stein et al, 2015; Galli et al, 2015) . This suggests that YAP interacts with MMB-regulated promoters through chromatin looping, resulting in the activation of a subset of cell cycle genes, similar to what we have recently described for human MCF10A cells (Pattschull et al, 2019) . Given that YAP not only interacts with MMB but that the MMB subunit B-MYB is also a transcriptional target of YAP, one can speculate that YAP and B-MYB form a positive feedback loop enabling expression of downstream cell cycle genes.
Remarkably, although LIN9 was required for cardiomyocyte cell cycle induction due to activated YAP, LIN9 was completely dispensable for homeostasis of the adult murine heart.
This absence of a phenotype in adult cardiac-specific Lin9 knockout mice was surprising, because LIN9 is a key subunit of the DREAM complex that is involved in repression of cell cycle genes in non-dividing cells (Sadasivam & DeCaprio, 2013) . The observation that the genetic inactivation of Lin9 in the postnatal heart is not associated with ectopic proliferation of cardiomyocytes suggests that loss of DREAM does not lead to de-repression of proproliferative genes. It is therefore possible that the main function of DREAM in cardiomyocytes is not to permanently silence cell cycle genes but to keep them in a poised state for reactivation by pro-proliferative signals. This notion is consistent with our finding that LIN9 remains associated with promoters of cell cycle genes in postnatal hearts and with the observation that DREAM binds in human cells to a nucleosome-free region at transcriptional start sites upstream from regions with high nucleosome density (Marceau et al, 2016) . Further support from such a model comes from the observation that cell cycle promoters, as opposed to genes that regulate cell-cell contacts and the cytoskeleton, are readily accessible in adult murine hearts before introduction of a YAP5SA transgene (Monroe et al, 2019) . Thus, LIN9
and DREAM may represent an epigenetic memory of a set of inactive but inducible cell cycle genes in postmitotic cardiomyocytes. It is therefore tempting to speculate that MuvB complexes play a dual role in cardiomyocyte proliferation, contributing to the inactive, but primed state of cell cycle genes as well as to their YAP-mediated activation. It will be important to investigate whether epigenetic changes at MuvB bound promoters contribute to the loss of the regeneration capacity in adult hearts (Quaife-Ryan et al, 2017) .
MATERIALS AND METHODS
Mice
Sav1 tm1.1Dupa /J mice were obtained from Jackson laboratories, in which LoxP sites flank exon 3 of the Sav1 gene (Cai et al, 2010) . We have previously descripted Lin9 fl mice, in which LoxP sites flank exon 7 of the Lin9 gene (Reichert et al, 2010) . Cardiomyocyte-specific deletion of Sav1 and Lin9 was achieved by crossing mice to Nkx2.5-Cre mice (Stanley et al, 2002) .
Postnatal cardiomyocyte-specific deletion of Sav1 and Lin9 was achieved by crossing mice to a-MHC-Cre mice (Agah et al, 1997) . To obtain Lin9 fl/fl CreER T2 , Lin9 fl mice were crossed with a mouse line ubiquitously expressing CreER T2 transgene (Hameyer et al, 2007) . Mice were maintained in a C57/Bl6 background.
Cell culture
HEK293A (Thermo Fisher Scientific) cells, HeLa (ATCC® CCL-2™, female) cells and C2C12 (ATCC® CRL-1772™) cells were maintained in DMEM supplemented with 10% FCS (Thermo Fisher Scientific) and 1% penicillin/streptomycin (Thermo Fisher Scientific). Differentiation of C2C12 cells was induced by culturing in DMEM medium with 2 % horse serum (Sigma).
Primary embryonic and postnatal cardiomyocytes were isolated by enzymatic digestion with the Pierce™ Primary cardiomyocyte isolation kit (Thermo Fisher Scientific). Cardiomyocytes were enriched by preplating on tissue-culture plastic to remove nonmyocytes. Cardiomyocytes were initially cultured for 48h on fibronectin-coated dishes with 5% horse serum (Sigma) and 1% penicillin/streptomycin (Thermo Fisher Scientific) and cardiomyocyte growth supplement at 37 °C and 5% CO2 to prevent proliferation of nonmyocytes. To induce the deletion of Lin9, conditional cardiomyocytes were treated with 100 nM 4-hydroxytamoxifen (Sigma) for 4 days.
Cardiomyocytes were transduced with adenovirus (multiplicity of infection, 25) in serum-free medium for 24 h and cultured for additional 48 h.
Adenovirus
Adenoviral constructs were constructed using the ViralPower adenoviral expression system (Thermo Fischer Scientific). Entry vectors containing YAPS127A, YAPS94AS127A and YAPS127AΔ155-263 were generated by PCR from p2xFLAG-CMV-YAPS127A (Komuro et al, 2003) . Entry vectors containing GFP, HA-NLS-B-MYB (2-241)-T2A-GFP and HA-NLS-B-MYB (2-241, ΔPPXY)-T2A-GFP were generated by PCR from pCDNA4/TO-HA-NLS-SV40-B-MYB (this work) and pSpCas9n(BB)-2A-GFP (PX461) (Addgene #48140). All entry vectors were subcloned into pENTR3C (Invitrogen) and then recombined into pAd/CMV/V5-DEST using LR clonase II (Thermo Fischer Scientific). The production of YAP mutant and LacZ adenoviruses was performed in HEK293A cells according to the manufacturer's instructions. Adenoviruses were titered using the Adeno-X Rapid Titer Kit (TaKaRa).
RT-qPCR
Total RNA was isolated using peqGOLD TriFast (Peqlab) according to the manufacturer's instructions. RNA was transcribed using 100 units RevertAid reverse transcriptase (Thermo Fisher Scientific). Quantitative real-time PCR reagents were from Thermo Fisher Scientific and real-time PCR was performed using the Mx3000 (Stratagene) detection system. Primer sequences are listed in Supplementary Table 1 . Expression differences were calculated as described before (Osterloh et al, 2007) . 
Immunoblotting and immunoprecipitation
Whole protein extracts were obtained by lysing cells in TNN buffer (50mM Tris (pH 7.5), 120mM NaCl, 5mM EDTA, 0.5% NP40, 10mM Na4P2O7, 2mM Na3VO4, 100mM NaF, 1mM PMSF, 1mM DTT, 10mM b-glycerophosphate, protease inhibitor cocktail (Sigma)). Protein lysates or purified protein were separated by SDS-PAGE, transferred to a PVDF-membrane and detected by immunoblotting with the first and secondary antibodies: β-actin (Santa Cruz Biotechnology, sc-47778) 1:5000, B-MYB (clone LX015.1, (Tavner et al, 2007) ) 1:5, anti-HA.11 (Covance, MMA-101P) 1:1000, anti-FLAG M2 (Sigma, F3165) 1:5000, anti-His (Sigma, H1029) 1:2000, Vinculin (Sigma, V9131) 1:10000, TOP2A (Santa Cruz Biotechnology, sc-365916) 1:1000, CDC20 (Santa Cruz Biotechnology, sc-5296) 1:500, YAP (Santa Cruz Biotechnology, sc-10199) 1:1000, p-YAP(S127A) (Cell Signaling Technology, 4911) 1:1000, LIN9 (Bethyl, A300-BL2981), NUSAP1 (Geert Carmeliet) 1:1000, CENPF (Abcam, ab-5) 1:1000, anti-mouse-HRP (GE healthcare, NXA931) 1:5000 and HRP Protein A (BD Biosciences, 610438) 1:5000. For immunoprecipitation of FLAG-tagged proteins, protein G dynabeads (Thermo Fisher Scientific) were first coupled with 1 µg FLAG-antibody (Sigma, F3165) and then immunoprecipitated with 1mg whole cell lysate. After five times of washing with TNN, proteins were separated by SDS-PAGE and detected by immunoblotting using the desired antibodies.
Immunostaining
For immunostaining cardiomyocytes were seeded onto fibronectin coated coverslips. HeLa cells were seeded onto coverslips without fibronectin. Cells were fixed with 3% paraformaldehyde and 2% sucrose in PBS for 10 minutes at room temperature. Cells were permeabilized using 0.2% Triton X-100 (Sigma) in PBS for 5 minutes and blocked with 3% 
Flow cytometry
Cardiomyocytes were isolated and enriched with the Pierce™ Primary cardiomyocyte isolation kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Isolated and enriched cardiomyocytes were fixed with 4% PFA in PBS for 5 minutes. Detection was performed using a Beckman Coulter FC 500 cytomics and data were analyzed in CXP analysis 2.2 software. Gating and compensation were based on fluorophore-negative controls. 10.000 cells were analyzed per genotype.
RNA-Seq
For whole transcriptome analysis, total RNA was isolated in triplicates from ventricular heart tissue with the desired genotype. DNA libraries were generated using 1µg RNA with the magnetic mRNA isolation module and NEBNext Ultra II RNA Library Prep Kit for Illumina (New England Biolabs). DNA library was amplified by 7 PCR cycles and quality was analyzed using the fragment analyzer (Advanced Analytical). Libraries were sequenced on the NextSeq 500 platform (Illumina).
ChIP-Seq
Chromatin was isolated from ventricular heart tissue of E16.5 or P10 hearts. In brief, minced tissue was fixed with 1% formaldehyde for 20 minutes at RT. The reaction was stopped by adding 125mM glycine for additional 5 minutes. Tissue was incubated in lysis buffer (50mM Tris-HCl pH8, 10mM EDTA, 1% SDS) for 1 hour at 4°C. Samples were sonicated for 1 minute at 25% amplitude (10s ON / 30s OFF) at 4°C, insoluble material was removed by centrifugation and chromatin was fragmented to an approximate size of 150 to 300bp by additional sonicating for 10 minutes at 25% amplitude (10 seconds On/ 30 seconds OFF) at 4°C using a Branson sonifier. Afterwards chromatin was diluted ten times in ChIP dilution buffer (50mM Tris-HCl pH8, 0.167M NaCl, 1.1% Triton X-100, 0.11% sodium deoxycholate). For immunoprecipitation, 9µg of the antibody was coupled to protein G dynabeads (Thermo Fisher Scientific) for 6 hours at 4°C and then incubated with fragmented chromatin over night at 4°C. Beads were washed in total twelve times with wash buffer I (50mM Tris-HCl pH8, 0.15M NaCl, 1mM EDTA, 0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate), wash buffer II (50mM Tris-HCl pH8, 0.5M NaCl, 1mM EDTA, 0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate), wash buffer III (50mM Tris-HCl pH8, 0.5M LiCl2, 1mM EDTA, 1% Nonidet P-40, 0.7% sodium deoxycholate) and wash buffer IV (10mM Tris-HCl pH8, 1mM EDTA). 1mM PMSF and protease inhibitor cocktail were added freshly to all buffers. After washing chromatin was eluted in (10mM Tris-HCl pH8, 0.3M NaCl, 5mM EDTA, 0.5% SDS, 10µg/ml RNAseA) and crosslink was reversed at 65°C over night. Proteins were digested by adding 200µg/ml proteinase K at 55°C for 2 hours. DNA was purified using the QIAquick PCR Purification Kit (QIAGEN) and eluted in 50 µl EB buffer. Purified ChIP-DNA was quantified using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific). DNA libraries were generated using 10ng purified ChIP-DNA and the NEBNext®Ultra IIDNALibrary Prep Kit for Illumina® (New England Biolabs) according to the manufacturer's instructions. DNA library was amplified by 12-15 PCR cycles and quality was analyzed using the fragment analyzer (Advanced Analytical). Libraries were sequenced on the NextSeq 500 platform (Illumina). The following antibodies were used for ChIP-Seq: LIN9 (Bethyl, A300-BL2981), YAP (NB110-58358) and IgG from rabbit serum (Sigma, I5006). 
GST-pulldown
Bioinformatic Analysis
After sequencing, bases were called using Illuminas GenerateFASTQ v1.1.0.64 software and sequencing quality was controlled with the FastQC script. For RNA-seq, reads were mapped with TopHat v2.1.0 and BOWTIE2 (Langmead & Salzberg, 2012) with default parameters to the murine genome (mm10). Samples were normalized to the sample with the smallest number of mappable reads and a read count matrix for each Ensembl gene (GRCm38.p6) was generated with the summarizeOverlaps function in the R package {GenomicFeatures}. Before differential gene expression analysis, non-or weakly expressed genes were removed using the threshold: mean read count per gene over all samples >1.
Differentially expressed genes were called with EdgeR and p-values were adjusted for multiple-testing with the Benjamini-Höchberg procedure (FDR: false discovery rate). Gene set enrichment analyses were performed with signal2noise metric, 1000 permutations and a combined gene set database comprising Hallmark and C2 gene sets.
For ChIP-seq, sequenced reads were mapped to the Mus musculus genome mm10 with BOWTIE v1.2 (Langmead & Salzberg, 2012) with default parameters and subsequently normalized to the sample with the smallest number of sequenced reads. Peaks were called with MACS14 (Zhang et al, 2008) with maximal 3 duplicates, a p-value cut-off of 1e-5 and the input sample as control. Resulting peaks were annotated to the next transcriptional start of Ensembl genes with the closestBed function from the bedtools suite v2.26.0 (Quinlan & Hall, 2010) . Overlapping peaks were identified with bedtools intersect and a minimal overlap of 1bp.
LIN9 occupancy was calculated in a window of +/-1kb around TSSs with bedtools coverage function. Density matrices were generated with deeptools v2.3.5. (Ramírez et al, 2014) computeMatrix function at a resolution of 1bp and subsequently used for plotting heat maps with plotHeatmap. Mapped ChIP-seq data for histone marks were taken from the ENCODE portal (Sloan et al, 2016) (https://www.encodeproject.org/) with the following identifiers: ENCFF056JGV, ENCFF295HNV, ENCFF642EEK, ENCFF687BWU. Promoters, enhancers and super-enhancers were defined as described previously (Pattschull et al, 2019) .
In box plots, the central line reflects the median, the borders of the boxes indicate the first and third quartile and whiskers extend to 1.5 of the interquartile range. Outliers are shown as dots.
P-values were calculated with a two-tailed Wilcoxon rank sum test (unpaired samples) or
Wilcoxons signed-rank test (paired samples).
ChIP-and RNA-sequencing datasets are available at the NCBI's Gene Expression Omnibus (Edgar et al, 2002) under the accession number GEO: GSE137132. were transduced with Ade-LacZ or with Ade-YAP(S127A) and treated with or without 4-OHT.
The fraction of pH3-positive cardiomyocytes was quantified. Error bars show SDs of biological replicates (n=3). E) and F) Cardiomyocytes were transduced with Ade-LacZ, Ade-YAP(S127A), and Ade-YAP(S127A/S94A) or with Ade-YAP(S127A/∆WW). The fraction of LacZ S127A S127A/S94A S127A/∆WW YAP-MMB targets YAP-only targets
